<![CDATA[Genmab — December 2012]]>@gen.co

]]>https://dev.proinvestor.com/forum/topic/451453/genmab-december-2012RSS for NodeFri, 19 Jun 2026 08:50:59 GMTMon, 03 Dec 2012 08:19:24 GMT60<![CDATA[Reply to Genmab — December 2012 on Sat, 29 Dec 2012 14:59:25 GMT]]>http://www.bcfjobs.nl/vac_pdf/9049.pdf

]]>https://dev.proinvestor.com/forum/post/10070806https://dev.proinvestor.com/forum/post/10070806Sat, 29 Dec 2012 14:59:25 GMT<![CDATA[Reply to Genmab — December 2012 on Fri, 28 Dec 2012 19:24:40 GMT]]>http://faculty.ccbcmd.edu/courses/bio141/lecguide/unit4/innate/c1act.html

]]>https://dev.proinvestor.com/forum/post/10070803https://dev.proinvestor.com/forum/post/10070803Fri, 28 Dec 2012 19:24:40 GMT<![CDATA[Reply to Genmab — December 2012 on Fri, 28 Dec 2012 08:40:20 GMT]]>På side 14 i vedlagte ses hexabodien, mener jeg at være kommet frem til http://www.dls.ym.edu.tw/imm/The Complement System-052506.pdf

]]>https://dev.proinvestor.com/forum/post/10070804https://dev.proinvestor.com/forum/post/10070804Fri, 28 Dec 2012 08:40:20 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 16:40:47 GMT]]>ok - mig bekendt er der ikke RA forsøg i gang med ofa

]]>https://dev.proinvestor.com/forum/post/10070801https://dev.proinvestor.com/forum/post/10070801Thu, 27 Dec 2012 16:40:47 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 15:51:01 GMT]]>Men du linker til Multiple Sclerose forsøget, der ligger ikke et på Reumatoid Artrit.

]]>https://dev.proinvestor.com/forum/post/10070802https://dev.proinvestor.com/forum/post/10070802Thu, 27 Dec 2012 15:51:01 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 15:42:50 GMT]]>
301 Moved Permanently

favicon

(www.clinicaltrials.gov)

]]>https://dev.proinvestor.com/forum/post/10070807https://dev.proinvestor.com/forum/post/10070807Thu, 27 Dec 2012 15:42:50 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 15:37:36 GMT]]>det er korrekt - vi skal høre nyt herfra først i 2013

]]>https://dev.proinvestor.com/forum/post/10070798https://dev.proinvestor.com/forum/post/10070798Thu, 27 Dec 2012 15:37:36 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 15:29:22 GMT]]>På GSK.com står Ofatumumab sc fase 2 i RA. http://www.gsk.com/investors/product-pipeline.html
Er det en fejl eller kører et sådant forsøg? Jeg kan ikke finde et på clinicaltrials.gov

]]>https://dev.proinvestor.com/forum/post/10070796https://dev.proinvestor.com/forum/post/10070796Thu, 27 Dec 2012 15:29:22 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 13:53:57 GMT]]>Kunne være interessant hvis dahanca havde 20-30 patienter på den nye version 🙂

]]>https://dev.proinvestor.com/forum/post/10070800https://dev.proinvestor.com/forum/post/10070800Thu, 27 Dec 2012 13:53:57 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 13:53:14 GMT]]>og her det gamle abstract der er kombi af to antibodies http://www.biomedexperts.com/Abstract.bme/21832160/Epidermal_growth_factor_receptor_EGFR_antibody-induced_antibody-dependent_cellular_cytotoxicity_plays_a_prominent_role

]]>https://dev.proinvestor.com/forum/post/10070795https://dev.proinvestor.com/forum/post/10070795Thu, 27 Dec 2012 13:53:14 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 13:52:32 GMT]]>
Link Preview Image
Domain Registered at Safenames

favicon

(www.biomedexperts.com)

]]>https://dev.proinvestor.com/forum/post/10070793https://dev.proinvestor.com/forum/post/10070793Thu, 27 Dec 2012 13:52:32 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 13:49:38 GMT]]>Det vil de ikke svare på 🙂

]]>https://dev.proinvestor.com/forum/post/10070799https://dev.proinvestor.com/forum/post/10070799Thu, 27 Dec 2012 13:49:38 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 13:49:32 GMT]]>Jeg har spurgt genmab om de har testet HexaBody på Zalutumumab

]]>https://dev.proinvestor.com/forum/post/10070792https://dev.proinvestor.com/forum/post/10070792Thu, 27 Dec 2012 13:49:32 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 13:38:53 GMT]]>Derfor tror jeg at det er ved disse forsøg at de har fundet nøglen til haxabody-platformen

]]>https://dev.proinvestor.com/forum/post/10070794https://dev.proinvestor.com/forum/post/10070794Thu, 27 Dec 2012 13:38:53 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 13:38:15 GMT]]>Det er flere år siden jeg læste et abstract med Zalu og et andet egfr stof der i kombi gav en helt vild respons - som jeg husker hel forsvinden af cancer.

]]>https://dev.proinvestor.com/forum/post/10070790https://dev.proinvestor.com/forum/post/10070790Thu, 27 Dec 2012 13:38:15 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 12:14:47 GMT]]>men det ser så faktisk ud som om de har afprøvet det med Zalu

]]>https://dev.proinvestor.com/forum/post/10070789https://dev.proinvestor.com/forum/post/10070789Thu, 27 Dec 2012 12:14:47 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 11:47:48 GMT]]>vildt!

]]>https://dev.proinvestor.com/forum/post/10070797https://dev.proinvestor.com/forum/post/10070797Thu, 27 Dec 2012 11:47:48 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 11:44:54 GMT]]>http://www.faqs.org/patents/imgfull/20110256142_22

]]>https://dev.proinvestor.com/forum/post/10070788https://dev.proinvestor.com/forum/post/10070788Thu, 27 Dec 2012 11:44:54 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 11:36:12 GMT]]>Dette skulle være Hexabody hemmeligheden

]]>https://dev.proinvestor.com/forum/post/10070791https://dev.proinvestor.com/forum/post/10070791Thu, 27 Dec 2012 11:36:12 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 11:35:18 GMT]]>0557] Combinations of EGFR antibody LC1006-003 with 2F8-IgG1, 2F8-IgG4 or 2F8-F(ab)2 were tested in their ability to bind C1q and C4c, and to induce CDC. A431 cell line was used as target. It was found that relevant complement-deposition and -lysis was only observed in the presence of two human IgG1 Fc fragments (FIGS. 15 and 16).

]]>https://dev.proinvestor.com/forum/post/10070785https://dev.proinvestor.com/forum/post/10070785Thu, 27 Dec 2012 11:35:18 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 11:33:35 GMT]]>[0553] FIG. 12 shows that while none of the individual EGFR antibodies and none of the cross-blocking combinations triggered CDC, most of the non cross-blocking combinations led to significant CDC on A431 cells (12a) and all non cross-blocking combinations led to significant CDC on A1207 cells (12b).

[0554] FIG. 13 shows CDC of A431 (13a) and A1207 (13b) cells in correlation to EGFR antibody concentration.

FIG. 12 shows that while none of the individual EGFR antibodies and none of th

]]>https://dev.proinvestor.com/forum/post/10070786https://dev.proinvestor.com/forum/post/10070786Thu, 27 Dec 2012 11:33:35 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 11:27:32 GMT]]>CDC trigges ikke med et ankelt antibody men sker med hexabody oplyser Genmab

]]>https://dev.proinvestor.com/forum/post/10070781https://dev.proinvestor.com/forum/post/10070781Thu, 27 Dec 2012 11:27:32 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 11:27:05 GMT]]>http://www.faqs.org/patents/app/20110256142

]]>https://dev.proinvestor.com/forum/post/10070783https://dev.proinvestor.com/forum/post/10070783Thu, 27 Dec 2012 11:27:05 GMT<![CDATA[Reply to Genmab — December 2012 on Thu, 27 Dec 2012 11:26:51 GMT]]>Hexabody omtales ikke direkte, men hvis man læser nederst i patentclaimet fremgår at lignende også kan bruges på mange andre target end egfr - og jeg tror de opdagede hvordan CDC bliver trigget

]]>https://dev.proinvestor.com/forum/post/10070780https://dev.proinvestor.com/forum/post/10070780Thu, 27 Dec 2012 11:26:51 GMT